PMID- 35195182
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220531
IS  - 1678-2674 (Electronic)
IS  - 0102-8650 (Print)
IS  - 0102-8650 (Linking)
VI  - 36
IP  - 11
DP  - 2022
TI  - Paeoniflorin mitigates PBC-induced liver fibrosis by repressing NLRP3 formation.
PG  - e361106
LID - S0102-86502021001100207 [pii]
LID - 10.1590/ACB361106 [doi]
LID - e361106
AB  - PURPOSE: To delve into the influence of paeoniflorin (PA) on abating primary 
      biliary cholangitis (PBC)-induced liver fibrosis and its causative role. METHODS: 
      Our team allocated the mice to control group, PA group, PBC group and PBC+PA 
      group. We recorded the weight change of mice in each group. We used Masson 
      staining for determining liver fibrosis, immunofluorescence staining for 
      measuring tumor necrosis factor-alpha (TNF-alpha) expression, quantitative real-time 
      polymerase chain reaction (qRT-PCR) for assaying related gene expression, as well 
      as Western blot for testing related protein expression. RESULTS: The weight of 
      PBC model mice declined. Twenty-four weeks after modeling, the positive rate of 
      anti-mitochondrial antibody-M2 (AMA-M2) in PBC mice reached 100%. Alkaline 
      phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase 
      (AST), hydroxyproline (HYP), laminin (LN), procollagen type III (PC III), and 
      malondialdehyde (MDA) contents saliently waxed (p<0.01). Meanwhile, superoxide 
      dismutase (SOD) and glutathione peroxidase (GSH-px) activity patently waned 
      (p<0.01). Liver fibrosis levels were flagrantly higher (p<0.01), and TNF-alpha, 
      NOD-like receptor protein 3 (NLRP3), caspase-1, interleukin-18 (IL-18), and 
      interleukin-1beta (IL-1beta) protein or gene expression were manifestly up-regulated 
      (p<0.01). PA could restore the weight of PBC mice, strikingly restrain the 
      positive expression of AMA-M2, and down-regulate serum ALP, ALT, AST, HYP, LN, PC 
      III, MDA in PBC mice (p<0.01). PA could also significantly up-regulate SOD and 
      GSH-px levels (p<0.01), down-regulate IL-1beta, IL-18, caspase-1, NLRP3, and TNF-alpha 
      protein or gene expression in PBC mice (p<0.01) and inhibit liver fibrosis levels 
      (p<0.01). CONCLUSIONS: PA can reduce PBC-induced liver fibrosis in mice and may 
      function by curbing the formation of NLRP3.
FAU - Zhang, Yizhe
AU  - Zhang Y
AUID- ORCID: 0000-0001-6754-6663
AD  - PhD. College of life Science - Zhengzhou University - Zhongyuan District - Henan 
      Province, China.
FAU - Zhang, Shujie
AU  - Zhang S
AUID- ORCID: 0000-0003-4880-9856
AD  - MS. College of life Science - Zhengzhou University - Zhongyuan District - Henan 
      Province, China.
FAU - Luo, Xin
AU  - Luo X
AUID- ORCID: 0000-0003-0379-8751
AD  - MS. College of life Science - Zhengzhou University - Zhongyuan District - Henan 
      Province, China.
FAU - Zhao, Han
AU  - Zhao H
AUID- ORCID: 0000-0002-6020-5054
AD  - BA. College of life Science - Zhengzhou University - Zhongyuan District - Henan 
      Province, China.
FAU - Xiang, Xiaoxing
AU  - Xiang X
AUID- ORCID: 0000-0002-6991-8149
AD  - PhD. Department of Gastroenterology - Taizhou people's Hospital affiliated to 
      Medical College of Yangzhou University - Jiangsu, China.
LA  - eng
PT  - Journal Article
DEP - 20220218
PL  - Brazil
TA  - Acta Cir Bras
JT  - Acta cirurgica brasileira
JID - 9103983
RN  - 0 (Glucosides)
RN  - 0 (Monoterpenes)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (Nlrp3 protein, mouse)
RN  - 21AIQ4EV64 (peoniflorin)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
SB  - IM
MH  - Animals
MH  - Aspartate Aminotransferases
MH  - Glucosides/*pharmacology
MH  - Liver/pathology
MH  - *Liver Cirrhosis/drug therapy/prevention & control
MH  - Mice
MH  - Monoterpenes/*pharmacology
MH  - *NLR Family, Pyrin Domain-Containing 3 Protein/metabolism
PMC - PMC8860402
COIS- Conflict of interest: Nothing to declare.
EDAT- 2022/02/24 06:00
MHDA- 2022/02/25 06:00
PMCR- 2022/02/18
CRDT- 2022/02/23 08:42
PHST- 2021/07/23 00:00 [received]
PHST- 2021/10/22 00:00 [accepted]
PHST- 2022/02/23 08:42 [entrez]
PHST- 2022/02/24 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2022/02/18 00:00 [pmc-release]
AID - S0102-86502021001100207 [pii]
AID - 10.1590/ACB361106 [doi]
PST - epublish
SO  - Acta Cir Bras. 2022 Feb 18;36(11):e361106. doi: 10.1590/ACB361106. eCollection 
      2022.